Immuneering Co. (NASDAQ:IMRX) Director Purchases $63,750.00

Immuneering Co. (NASDAQ:IMRX – Get Free Report) Director Peter Feinberg acquired 25,000 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were bought at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the acquisition, the director now directly owns 111,766 shares […]

Related Keywords

Peter Feinberg , Immuneering Company Profile , Virtu Financial , Nuveen Asset Management , Immuneering Corporation , Nasdaq , Vanguard Group Inc , Securities Exchange Commission , Jefferies Financial Group , Oracle Alpha Inc , Immuneering Co , Needham Company , Barclays Plc , Get Free Report , Director Peter Feinberg , Exchange Commission , Stock Down , Asset Management , Oracle Alpha , Financial Group , Chardan Capital , Investigational New Drug , Immuneering Daily , Immuneering , Nasdaq Imrx , Imrx , Medical , Insider Trading , Nsider Trades , Stocks ,